Intellia Therapeutics, Inc. (NTLA) financial statements (2021 and earlier)

Company profile

Business Address 40 ERIE STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments59728059341273
Cash and cash equivalents1605759341273
Short-term investments437223   
Receivables258106
Other undisclosed current assets17525942
Total current assets:617289325355281
Noncurrent Assets
Operating lease, right-of-use asset3919
Property, plant and equipment1618171511
Long-term investments and receivables 5   
Long-term investments 5   
Other noncurrent assets53567
Total noncurrent assets:6045222118
TOTAL ASSETS:676334347376299
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3617131011
Accounts payable104325
Accrued liabilities26131186
Deferred revenue2313
Debt 6   
Deferred revenue and credits2120
Contract with customer, liability27
Other undisclosed current liabilities6    
Total current liabilities:6436413131
Noncurrent Liabilities
Long-term debt and lease obligation3413   
Operating lease, liability3413
Liabilities, other than long-term debt5116294458
Deferred revenue and credits4458
Deferred revenue5116
Contract with customer, liability29
Other liabilities  000
Total noncurrent liabilities:8529294458
Total liabilities:14964697689
Stockholders' equity
Stockholders' equity attributable to parent527270278301210
Common stock00000
Additional paid in capital962570479422263
Accumulated other comprehensive income (loss)00(0)  
Accumulated deficit(435)(301)(201)(121)(54)
Total stockholders' equity:527270278301210
TOTAL LIABILITIES AND EQUITY:676334347376299

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net2616
Gross profit:5843302616
Operating expenses(195)(149)(121)(96)(49)
Operating loss:(137)(106)(91)(70)(32)
Nonoperating income
(Investment Income, Nonoperating)
27621
Net loss available to common stockholders, diluted:(134)(100)(85)(68)(32)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(134)(100)(85)(68)(32)
Comprehensive loss:(134)(100)(85)(68)(32)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)  
Comprehensive loss, net of tax, attributable to parent:(134)(99)(85)(68)(32)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: